Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated

Thromb Haemost. 1987 Dec 18;58(4):1049-52.

Abstract

Eleven severely affected haemophilia A patients (aged 6-42 y) with F VIII:C inhibitor (high responders) were treated with high-dose F VIII in order to eliminate the inhibitors. The patients comprise Danish high responder patients treated during the period 1977-1985. In all patients the inhibitors decreased significantly. In six, the inhibitor apparently disappeared (detection limit 0.4 Bethesda Units per ml) (BU/ml), in four patients a low level inhibitor of 0.4-1.4 BU/ml persisted. One patient is still on high-dose schedule. The duration of high-dose treatments ranged from less than one month up to 18 months. In all patients the tendency to spontaneous bleedings vanished when a measurable VIII:C level appeared in the post-infusion sample. The inhibitor suppression has allowed for extensive physical training and rehabilitation orthopaedic surgery. The patients are now able to conduct a normal haemophilic life on self-administered prophylactic doses of F VIII.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Clinical Trials as Topic
  • Factor VIII / administration & dosage*
  • Factor VIII / antagonists & inhibitors
  • Factor VIII / therapeutic use
  • Hemophilia A / blood
  • Hemophilia A / drug therapy*
  • Hemophilia A / immunology
  • Humans
  • Immune Tolerance
  • Immunosuppression Therapy
  • Male

Substances

  • Factor VIII